Inotersen API is a pharmaceutical-grade antisense oligonucleotide (ASO) designed for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. It selectively binds to transthyretin (TTR) messenger RNA (mRNA), promoting its degradation and reducing the production of transthyretin protein responsible for amyloid deposition.
By lowering circulating transthyretin levels, Inotersen helps slow disease progression, preserve neurological function, and improve quality of life in patients with hereditary transthyretin amyloidosis. It is administered as a subcutaneous injectable formulation.
Manufactured under WHO-GMP-certified facilities, our Inotersen API is produced using advanced oligonucleotide synthesis technologies to ensure exceptional purity, stability, biological activity, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Inotersen API is used in injectable pharmaceutical formulations for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy.
Inotersen binds to transthyretin (TTR) mRNA, promoting its degradation and reducing TTR protein production, thereby limiting amyloid deposition.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Inotersen API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp